Virpax Pharmaceuticals Engages New England Investors to Direct Licensing Strategy for Envelta™ in China

“We have engaged New England Investors, a life-sciences advisory firm, to represent us in our licensing efforts in China for Envelta,” stated Anthony P. Mack, Chairman and CEO of Virpax Pharmaceuticals. “New England Investors has offices in the United States along with mainland China and Singapore. We believe that their China focus, along with their cross-border transactional experience in both pre-clinical and clinical pharmaceutical products, makes them an outstanding partner for us.

“Overall, we believe we have a team of leading professionals in their fields to assist us as we move into the next phase of our development as a pharmaceutical company focused on pain and CNS disorders. We look forward to working with our teams on our product candidates and believe that Virpax will benefit greatly from their knowledge and experience,” concluded Mr. Mack.

“We believe that Virpax’s Envelta product under development for acute and chronic pain may be of interest to a number of Chinese pharmaceutical companies. The MET delivery system which crosses the blood brain barrier, is of special interest as it can potentially avoid the numerous side effects of pain medication currently in use. A patent for Envelta has recently been filed in China and we intend to begin our efforts with our Chinese colleagues shortly,” commented Mr. David Place, Managing Director of New England Investors, LLC.

Envelta is being funded under an in-kind grant from the National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health (NIH), awarded to Virpax in August of 2020. The product candidate is an intranasal spray of enkephalin nanoparticles that uses Molecular Envelope Technology (MET) as its delivery system to cross the blood brain barrier via the olfactory route while bypassing the liver.

About New England Investors LLC

New England Investors LLC (“NEI”) (http://www.newenglandinvestorsllc.com) is an advisory firm to North American and European biotech/pharmaceutical companies seeking to monetize their early and mid-stage assets via out-license to companies based in the People’s Republic of China, while also working with China domestic pharmaceutical companies seeking to out-license to the West. For more than 15 years, NEI has advised a broad range of clients including large, multinational Fortune 500 companies and early-stage companies, also acting as principal on its own behalf in several transactions.

About Virpax Pharmaceuticals

Virpax is developing branded, non-addictive pain management products candidates using its proprietary technologies to optimize and target drug delivery. Virpax is initially seeking FDA approval for two prescription drug candidates that employ two different patented drug delivery platforms. Probudur™ is a single injection liposomal bupivacaine formulation being developed to manage post-operative pain and Envelta™ is an intranasal molecular envelope enkephalin formulation being developed to manage acute and chronic pain, including pain associated with cancer. Virpax is also using its intranasal Molecular Envelope Technology (MET) to develop two other product candidates. PES200 is a product candidate being developed to manage post-traumatic stress disorder (PTSD) and NobrXiol™ is a product candidate being developed for the nasal delivery of a pharmaceutical-grade cannabidiol (CBD) for the management of rare pediatric epilepsy. Virpax acquired global rights to NobrXiol. Virpax is also seeking approval of two nonprescription product candidates: AnQlar, which is being developed to inhibit viral replication caused by influenza or SARS-CoV-2, and Epoladerm™, which is a topical diclofenac spray film formulation being developed to manage pain associated with osteoarthritis. For more information, please visit virpaxharma.com and follow us on Twitter, LinkedIn and YouTube.

Forward-Looking Statement

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s planned clinical trials, product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions.

These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or the Company’s financial performance and involve known and unknown risks, uncertainties, and other factors, including the Company’s ability to successfully complete research and further development and commercialization of Company drug candidates in current or future indications; the uncertainties inherent in clinical testing; our ability to manage and successfully complete clinical trials and the research and development efforts for multiple product candidates at varying stages of development; the effects of the outbreak of COVID-19 on our business and results of operations; the timing, cost and uncertainty of obtaining regulatory approvals for our product candidates; our ability to protect the Company’s intellectual property; the loss of any executive officers or key personnel or consultants; competition; changes in the regulatory landscape or the imposition of regulations that affect the Company’s products; our ability to continue to obtain capital to meet our long-term liquidity needs on acceptable terms, or at all, including the additional capital which will be necessary to complete clinical trials that we plan to initiate; and other factors listed under “Risk Factors” in our annual report on Form 10-K and quarterly reports on Form 10-Q that we file with the U.S. Securities and Exchange Commission.. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230131005119/en/